A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors

被引：0
|
作者：
Jonathan Metts
Brittany Harrington
Emad Salman
Scott M. Bradfield
Jennifer Flanary
Maua Mosha
Ernest Amankwah
Stacie Stapleton
机构：
[1] Johns Hopkins All Children’s Hospital,Cancer and Blood Disorders Institute
[2] Hospital Medicine,Division of Pediatric Hematology/Oncology
[3] MyMichigan Health,Data Coordinating Center for Pediatric Multicenter Studies
[4] Golisano Children’s Hospital of Southwest Florida,Department of Oncology
[5] Nemours Children’s Health,undefined
[6] Institute for Clinical and Translational Research,undefined
[7] Johns Hopkins All Children’s Hospital,undefined
[8] Johns Hopkins University School of Medicine,undefined
来源：
Child's Nervous System | 2022年 / 38卷
关键词：
Phase I; Pediatric; Brain tumor; Irinotecan; Temozolomide; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 928
页数：9
相关论文
共 50 条
  • [31] Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Wagner, LM
    Crews, KR
    Iacono, LC
    Houghton, PJ
    Fuller, CE
    McCarville, MB
    Goldsby, RE
    Albritton, K
    Stewart, CF
    Santana, VM
    CLINICAL CANCER RESEARCH, 2004, 10 (03) : 840 - 848
  • [32] Phase I study of intraventricular infusions of autologous exvivo expanded NK cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system
    Khatua, Soumen
    Gopalakrishnan, Vidya
    Cooper, Laurence
    Lee, Dean
    Sandberg, David I.
    Rytting, Michael
    Johnson, Jason J.
    Ketonen, Leena
    Liu, Diane
    Moyes, Judy
    Zaky, Wafik
    CANCER RESEARCH, 2017, 77
  • [33] A phase I trial of pomalidomide for children with recurrent, progressive/refractory central nervous system (CNS) tumors: A Pediatric Brain Tumor Consortium (PBTC) study.
    Fangusaro, Jason R.
    Mitchell, Duane Anthony
    Kocak, Mehmet
    Onar-Thomas, Arzu
    Sadighi, Zsila Sousan
    Baxter, Patricia Ann
    Hwang, Eugene I.
    Huang, Jianping
    Dunkel, Ira J.
    Fouladi, Maryam
    Warren, Katherine E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study
    Roger J. Packer
    Brian R. Rood
    David C. Turner
    Clinton F. Stewart
    Michael Fisher
    Christopher Smith
    Tina Young-Pouissant
    Stewart Goldman
    Rishi Lulla
    Anu Banerjee
    Ian Pollack
    Larry Kun
    Arzu Onar-Thomas
    Shengjie Wu
    James M. Boyett
    Maryam Fouladi
    Journal of Neuro-Oncology, 2015, 121 : 217 - 224
  • [35] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study
    Packer, Roger J.
    Rood, Brian R.
    Turner, David C.
    Stewart, Clinton F.
    Fisher, Michael
    Smith, Christopher
    Young-Pouissant, Tina
    Goldman, Stewart
    Lulla, Rishi
    Banerjee, Anu
    Pollack, Ian
    Kun, Larry
    Onar-Thomas, Arzu
    Wu, Shengjie
    Boyett, James M.
    Fouladi, Maryam
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (01) : 217 - 224
  • [36] Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial
    Fangusaro, Jason
    Mitchell, Duane A.
    Kocak, Mehmet
    Robinson, Giles W.
    Baxter, Patricia Ann
    Hwang, Eugene I.
    Huang, Jianping
    Onar-Thomas, Arzu
    Dunkel, Ira J.
    Fouladi, Maryam
    Warren, Katherine E.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (02)
  • [37] Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB).
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Leyco, Samantha
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease
    Melisko, Michelle E.
    Assefa, Michael
    Hwang, Jimmy
    DeLuca, Amy
    Park, John W.
    Rugo, Hope S.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) : 401 - 408
  • [39] Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease
    Michelle E. Melisko
    Michael Assefa
    Jimmy Hwang
    Amy DeLuca
    John W. Park
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2019, 177 : 401 - 408
  • [40] Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
    Bagatell, Rochelle
    Norris, Robin Elizabeth
    Ingle, Ashish M.
    Ahern, Charlotte H.
    Saggio, Jennifer
    Little, Anthony
    Weigel, Brenda
    Blaney, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345